Komori
Presentation materials for financial results7745A&D HOLON Holdings Company,LimitedElectrical Equipment and Precision Instruments

Financial Results Presentation for the Fiscal Year Ending March 2026

For the fiscal year ended March 2026, revenue and operating profit exceeded the previous fiscal year, while net income declined due to extraordinary losses related to costs for addressing violations of the Measurement Act and inappropriate expenditures at a Korean subsidiary. The Company also fell short of its full-year plan in some areas. The earnings forecast for the fiscal year ending March 2027 was revised downward to lower revenue and lower profit, and the numerical targets in the medium-term management plan were also reduced.

Worth reading
83Important
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
243
¥ million
Wording
Conditional
How definitive the wording is.

Contents of this document

Presentation materials for financial resultsFiscal year ending March 2026, full year13 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥69,326 million+3.3%
Operating profit¥9,209 million+4.5%
Ordinary income¥9,470 million+5.8%
Net income¥5,923 million-8.4%
Gross Profit Margin45.4%
Operating profit margin13.3%
Selling, general and administrative expenses¥22,241 million
Results for the three months of the current quarter
Net Sales
¥20,694 million
Operating profit
¥3,561 million
Full-year earnings forecast
Fiscal year ending March 2027
Net Sales
¥68,000 million
Operating profit
¥7,000 million
Ordinary income
¥6,900 million
Profit attributable to owners of the parent
¥4,500 million
Earnings per share
¥164.31
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales99.0%
Operating profit96.9%
Ordinary income100.7%
Profit attributable to owners of the parent91.1%
Earnings per share91.1%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Revenue was broadly in line with the plan, while operating profit was below the initial plan and slightly below the full-year forecast
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Operating profit
Impact on sales351
Impact of changes in costs406
Impact of changes in miscellaneous expenses-647
Foreign exchange impact on sales and miscellaneous expenses286
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Assumed Exchange Rates
US dollars¥150.00 per US dollar
Russian rubleRUB1.00 = ¥1.90
New initiatives
  • Release of the next-generation CD-SEM HSS-1000
  • Construction and start of operations at the new ホロン plant
  • Acquisition of an inspection equipment business in North America
  • Joint research program with Jichi Medical University
  • Construction of a new R&D center building
  • Restructuring of domestic production sites
  • AI and DX investment
  • Establishment of a Global Marketing Division
Key KPIsA metric the company considers important as a management benchmark.
  • ROE12.9 %
    Year on year against the same period last year-3.2 percentage points
  • Equity ratio65.7 %
  • Number of IR meetings98 times
  • Number of Measurement Act corrective actions completed1,741 Units
  • Progress rate for Measurement Act corrective actions34.1 %
  • Training participation rate100 %
  • PBR2.12 times
  • PER15.03 times
Segment results
Semiconductor-Related Business
Net Sales
¥11,114 million-9.6%
Operating profit
¥3,628 million-12.0%
Measurement and weighing instruments business
Net Sales
¥31,545 million+2.9%
Operating profit
¥3,387 million+25.7%
Medical and healthcare equipment business
Net Sales
¥26,667 million+10.5%
Operating profit
¥4,009 million-1.8%
Medium-term management plan targets
Revised FY2027
Net Sales
755 Hundreds of millions of yen
Operating profit
99 Hundreds of millions of yen
FY2034
Net Sales
1,500 Hundreds of millions of yen
Operating profit
300 Hundreds of millions of yen
Financial targets
ROICA management structure based on the ROIC approach is under development
Equity ratio
Actual results65.7 %
Market Size / Share
PBRHas remained at a PBR of 1x or higher
PERHas remained below the 18x average PER for the Tokyo Stock Exchange Prime Market
Orders received and order backlog
Order backlog
Semiconductor-Related Business
¥3,359 million
Measurement and weighing instruments business
¥5,228 million
Medical and healthcare equipment business
¥543 million
Capital expenditures
¥3,797 million
Annual Dividend
Fiscal year ending March 2026
Annual¥55
Interim¥25
End of period¥30
Forecast for the fiscal year ending March 2027
Annual¥60
Interim¥30
End of period¥30
Payout ratio
Forecast for the fiscal year ending March 202736.5 %
Total shareholder return target for the period¥6 billion or more
Contents of this document
ItemDetails
Document typePresentation materials for financial results
Fiscal Period CoveredFiscal year ending March 2026, full year
Net Sales¥69,326 million (YoY +3.3%)
Operating profit¥9,209 million (YoY +4.5%)
Ordinary income¥9,470 million (YoY +5.8%)
Net income¥5,923 million (YoY -8.4%)
Gross Profit Margin45.4%
Operating profit margin13.3%
Selling, general and administrative expenses¥22,241 million
Results for the three months of the current quarterNet Sales ¥20,694 million / Operating profit ¥3,561 million
Full-year earnings forecastFiscal year ending March 2027 Net Sales ¥68,000 million / Operating profit ¥7,000 million / Ordinary income ¥6,900 million / Profit attributable to owners of the parent ¥4,500 million / Earnings per share ¥164.31
Progress against full-year forecastNet Sales 99.0% / Operating profit 96.9% / Ordinary income 100.7% / Profit attributable to owners of the parent 91.1% / Earnings per share 91.1%
Self-assessment against the planRevenue was broadly in line with the plan, while operating profit was below the initial plan and slightly below the full-year forecast
Segment resultsSemiconductor-Related Business Net Sales ¥11,114 million (YoY -9.6%) / Operating profit ¥3,628 million (YoY -12.0%) / Measurement and weighing instruments business Net Sales ¥31,545 million (YoY +2.9%) / Operating profit ¥3,387 million (YoY +25.7%) / Medical and healthcare equipment business Net Sales ¥26,667 million (YoY +10.5%) / Operating profit ¥4,009 million (YoY -1.8%)
Breakdown of Factors Affecting the ChangeOperating profit Impact on sales 351 / Impact of changes in costs 406 / Impact of changes in miscellaneous expenses -647 / Foreign exchange impact on sales and miscellaneous expenses 286
Key KPIsIndicator name ROE / Value 12.9 % / Year on year against the same period last year -3.2 percentage points, Indicator name Equity ratio / Value 65.7 %, Indicator name Number of IR meetings / Value 98 times, Indicator name Number of Measurement Act corrective actions completed / Value 1,741 Units, Indicator name Progress rate for Measurement Act corrective actions / Value 34.1 %, Indicator name Training participation rate / Value 100 %, Indicator name PBR / Value 2.12 times, Indicator name PER / Value 15.03 times
Assumptions Underlying the Business OutlookAssumed Exchange Rates US dollars ¥150.00 per US dollar / Russian ruble RUB1.00 = ¥1.90
Medium-term management plan targetsRevised FY2027 Net Sales 755 Hundreds of millions of yen / Operating profit 99 Hundreds of millions of yen / FY2034 Net Sales 1,500 Hundreds of millions of yen / Operating profit 300 Hundreds of millions of yen
Financial targetsROE Not disclosed / ROIC A management structure based on the ROIC approach is under development / Equity ratio Actual results 65.7 %
Annual DividendFiscal year ending March 2026 Annual ¥55 / Interim ¥25 / End of period ¥30 / Forecast for the fiscal year ending March 2027 Annual ¥60 / Interim ¥30 / End of period ¥30
Payout ratioForecast for the fiscal year ending March 2027 36.5 % / Total shareholder return target for the period ¥6 billion or more
Capital expenditures¥3,797 million
Orders received and order backlogOrder backlog Semiconductor-Related Business ¥3,359 million / Measurement and weighing instruments business ¥5,228 million / Medical and healthcare equipment business ¥543 million
Market Size / SharePBR Has remained at a PBR of 1x or higher / PER Has remained below the 18x average PER for the Tokyo Stock Exchange Prime Market
New initiativesRelease of the next-generation CD-SEM HSS-1000, Construction and start of operations at the new ホロン plant, Acquisition of an inspection equipment business in North America, Joint research program with Jichi Medical University, Construction of a new R&D center building, Restructuring of domestic production sites, AI and DX investment, Establishment of a Global Marketing Division
Items this document does not state (6)
Unit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookAcquisition of treasury sharesKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The Company recorded ¥552 million in costs for corrective measures related to violations of the Measurement Act and a ¥243 million loss from embezzlement at a Korean subsidiary as extraordinary losses. The shortfall against the initial plan for operating profit for the fiscal year was attributed to the impact of U.S. tariffs and increases in various costs. From the fiscal year ending March 2027 onward, the earnings forecast was revised in light of a temporary adjustment in semiconductor investment in the Chinese market, slower growth in the EV-related market, U.S. tariffs, and foreign exchange effects.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results Presentation for the Fiscal Year Ending March 2026 | A&D HOLON Holdings Company,Limited (7745) timely disclosure | Komori